» Articles » PMID: 20544233

LRRK2 G2019S Mutation: Frequency and Haplotype Data in South African Parkinson's Disease Patients

Overview
Specialties Neurology
Physiology
Date 2010 Jun 15
PMID 20544233
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most significant genetic cause of Parkinson's disease (PD). The exact function of LRRK2 is currently unknown but the presence of multiple protein interaction domains including WD40 and ankyrin indicates that it may act a scaffold for assembly of a multi-protein signaling complex. The G2019S mutation in LRRK2 represents the most clinically relevant PD-causing mutation and has been found in both familial and sporadic forms of the disorder. This mutation is situated in the highly conserved kinase MAPKKK domain, and has been found in up to 40% of PD patients from North African Arabic, 30% of Ashkenazi Jewish and approximately 10% of Portuguese and Spanish populations. Although extensively investigated in numerous European and North American populations, studies on the frequency of G2019S in African countries have been rare. The present study is the first on the South African population. High-resolution melt analysis was used to identify the G2019S mutation and it was found in 2% (4/205) of the patients studied. G2019S was not found in any of the Black PD patients screened. In all four G2019S-positive probands the mutation was shown to be present on the common haplotype referred to as haplotype 1. This reveals that the four South African G2019S-positive probands (three Caucasian and one of mixed ancestry) share a common ancestor with the other haplotype 1-associated families reported worldwide.

Citing Articles

The Landscape of Monogenic Parkinson's Disease in Populations of Non-European Ancestry: A Narrative Review.

Koros C, Bougea A, Simitsi A, Papagiannakis N, Angelopoulou E, Pachi I Genes (Basel). 2023; 14(11).

PMID: 38003040 PMC: 10671808. DOI: 10.3390/genes14112097.


Leveraging genetic diversity to understand monogenic Parkinson's disease's landscape in AfrAbia.

Mohamed W Am J Neurodegener Dis. 2023; 12(4):108-122.

PMID: 37736165 PMC: 10509492.


Parkinson's genetics research on underrepresented AfrAbia populations: current state and future prospects.

Mohamed W Am J Neurodegener Dis. 2023; 12(2):23-41.

PMID: 37213711 PMC: 10195393.


Neurexin 2 p.G849D variant, implicated in Parkinson's disease, increases reactive oxygen species, and reduces cell viability and mitochondrial membrane potential in SH-SY5Y cells.

Cuttler K, de Swardt D, Engelbrecht L, Kriel J, Cloete R, Bardien S J Neural Transm (Vienna). 2022; 129(12):1435-1446.

PMID: 36242655 DOI: 10.1007/s00702-022-02548-8.


Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Yilmazer S, Candas E, Genc G, Alaylioglu M, Sengul B, Gunduz A Neuromolecular Med. 2020; 23(2):292-304.

PMID: 33015738 DOI: 10.1007/s12017-020-08619-x.


References
1.
Lesage S, Patin E, Condroyer C, Leutenegger A, Lohmann E, Giladi N . Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum Mol Genet. 2010; 19(10):1998-2004. DOI: 10.1093/hmg/ddq081. View

2.
Guo L, Wang W, Chen S . Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int J Biochem Cell Biol. 2006; 38(9):1469-75. DOI: 10.1016/j.biocel.2006.02.009. View

3.
Marin I, van Egmond W, van Haastert P . The Roco protein family: a functional perspective. FASEB J. 2008; 22(9):3103-10. DOI: 10.1096/fj.08-111310. View

4.
Correia Guedes L, Ferreira J, Rosa M, Coelho M, Bonifati V, Sampaio C . Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord. 2009; 16(4):237-42. DOI: 10.1016/j.parkreldis.2009.11.004. View

5.
Zhang Z, Burgunder J, An X, Wu Y, Chen W, Zhang J . LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Mov Disord. 2009; 24(13):1902-5. DOI: 10.1002/mds.22371. View